The topic of the article below did not get much coverage in the media….. and that is unfortunate….. the issue should be important to all
Specialty pharmacies have, presumably, been preparing to implement new workflows to accommodate the anticipated January launch of new CMS regulations related to copay accumulator transactions.
The FDA recently approved a new form of therapy for ALS. Normally, a new form is not big news, but, for this therapy, it may
The FDA recently approved the fourth pegfilgrastim biosimilar referencing Neulasta, Fylnetra (pegfilgrastim-pbbk) from Amneal Pharmaceuticals. Fylnetra is a leukocyte growth factor indicated to decrease the